Board of Regents of the University of Wisconsin System

1. Ipsen Biopharmaceuticals, Inc $3,886,631 31 payments
2. Eisai Inc. $2,026,200 387 payments
3. Novartis Pharmaceuticals Corporation $1,704,457 36 payments
4. Mirati Therapeutics, Inc. $1,563,049 19 payments
5. Pfizer Inc. $1,116,540 368 payments
6. Celgene Corporation $962,570 18 payments
7. CSL Behring $958,313 278 payments
8. Shire North American Group Inc $914,068 54 payments
9. Regeneron Pharmaceuticals, Inc. $585,965 99 payments
10. GlaxoSmithKline, LLC. $512,141 66 payments

1. Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma $1,527,289 13 payments
2. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $1,465,127 16 payments
3. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $890,690 35 payments
4. C1 Inhibitor for the Treatment of Acute Antibody-Mediated Renal Allograft Rejection in A Model of Kidney Transplantation in Rhesus MacAques $827,638 1 payment
5. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $541,070 31 payments
6. Phase II Study of Nanoliposomal Irinotecan With Tas102 and Bevacizumab for Patients With Metastatic Colorectal Cancer $497,880 2 payments
7. An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) $349,695 224 payments
8. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant $340,599 33 payments
9. PhIII Ide-Cel vs Triplet Regimens RRMM 3L (bb2121-MM-003; KarMMa-3) - A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRM $321,576 2 payments
10. A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer $320,856 2 payments

1. Non-patient care $1,382,679 8 payments
2. Patient care $217,017 15 payments
3. Other $60,168 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.